Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% (HP/TAZ) Lotion in Patients with Baseline Body Surface Area of 6 -12%

Main Article Content

Linda Stein Gold
Jonathan S Weiss
Lawrence Green
Leon Kircik
Lauren Miller
Abby Jacobson
Susan Harris

Keywords

Psoriasis, Corticosteroid, Halobetasol, Tazarotene, Retinoid

Abstract

Abstract not available.

References

1. Weigle N, et al. Am Fam Physician. 2013;87(9):626-633.

2. Torsekar R, et al. Indian Dermatol Online J. 2017;8(4):235-245.

3. Stein Gold L, et al. J Am Acad Dermatol. 2018;79(2):287-293.

4. Sugarman JL, et al. J Drugs Dermatol. 2018;17(8):855-861.